Kovo Health Tech - Senior VP of Finance, Mark Detz
Senior VP of Finance, Mark Detz
Source: Newsfile Corp.
  • Kovo HealthTech (KOVO) has appointed Mark Detz, CPA, CA as Senior Vice President of Finance
  • Mark previously held several senior positions with Anheuser-Busch and holds an undergraduate degree from the Schulich School of Business
  • Kovo HealthTech is a growing healthcare technology company that specializes in billing-as-a-service
  • Kovo HealthTech Corporation (KOVO) opened trading at C$0.39 per share

Kovo HealthTech (KOVO) has appointed veteran finance expert Mark Detz, CPA, CA as its Senior Vice President of Finance.

Before joining Kovo, Detz held several senior positions with Anheuser-Busch, where he focused on strategy and financial operations, including financial reporting, forecasting, budgeting, mergers and acquisitions. Detz began his career as an auditor at KPMG and holds an undergraduate degree from the Schulich School of Business.

“As we look to continue to scale our business operations in 2022 through strategic acquisitions and organic growth, we’re excited to welcome Mark to the Kovo team,” says Kovo CFO Inder Saini.

“Mark’s entrepreneurial, disciplined approach and track-record with world-leading innovators like Anheuser-Busch and KPMG, will be instrumental in driving Kovo’s aggressive 2022 growth strategy,” he explains.

Kovo HealthTech is a growing healthcare technology company that specializes in billing-as-a-service.

The company helps healthcare providers seamlessly digitally track and manage complex patient care registration, services, billing, and payments using its proprietary OneRev technology platform.

Kovo HealthTech Corporation (KOVO) opened trading at C$0.39 per share.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

BlackBerry expands AI-powered cybersecurity service

BlackBerry (TSX:BB) releases the new and expanded CylanceMDR, a managed detection and response tool backed by its Cylance AI platform.

Qualcomm stock jumps on Q2 2024 earnings

Qualcomm (NDAQ:QCOM) shares rise nearly 10 per cent early Thursday on better-than-expected adjusted earnings and strong revenue guidance.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.